A5042565417- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- HIV, Drug Use, Sexual Risk
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Herpesvirus Infections and Treatments
- Cytomegalovirus and herpesvirus research
- Tuberculosis Research and Epidemiology
- Bone and Joint Diseases
- T-cell and Retrovirus Studies
- Polyomavirus and related diseases
- Pneumonia and Respiratory Infections
- Liver Disease and Transplantation
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
- Sex work and related issues
- Vitamin D Research Studies
- Adolescent Sexual and Reproductive Health
- Syphilis Diagnosis and Treatment
Instituto Ramón y Cajal de Investigación Sanitaria
2016-2025
Instituto de Salud Carlos III
2001-2025
Hospital Universitario Ramón y Cajal
2016-2025
Bristol-Myers Squibb (United States)
2024
Centro de Investigación Biomédica en Red
2021-2024
Universidad de Alcalá
1999-2023
GTx (United States)
2023
Centro de Investigación en Red en Enfermedades Cardiovasculares
2023
Instituto Cajal
2011-2022
Hospital Universitario Príncipe de Asturias
2020
A low CD4/CD8 ratio has been identified in the general population as a hallmark of inmmunosenescence and surrogate all-cause mortality. We aimed to investigate treated HIV-infected individuals relationship between serious non-AIDS events.
The protein kinase C (PKC) agonist bryostatin-1 has shown significant ex-vivo potency to revert HIV-1 latency, compared with other latency reversing agents (LRA). safety of this candidate LRA remains be proven in treated HIV-1-infected patients.In pilot, double-blind phase I clinical-trial (NCT 02269605), we included aviraemic patients on triple antiretroviral therapy evaluate the effects two different single doses (10 or 20 μg/m) placebo.Twelve were included, four each arm. Bryostatin-1 was...
In vitro studies have shown good activity of linezolid against Mycobacterium tuberculosis, including multidrug-resistant strains. However, clinical experience with in tuberculosis is scarce.We report our five consecutive patients infection treated combination regimens that included linezolid.Two had bovis infection, resistance to 12 antituberculous agents (one them HIV co-infection and <50 CD4 cells/mm(3)). The other three were infected by M. strains, all first-line drugs second-line drugs....
Background: Prior attempts to reduce the number of drugs needed maintain viral suppression in patients with suppressed HIV replication while receiving three antiretroviral have been unsuccessful. Methods: In 205 on lopinavir-ritonavir and two nucleosides, this randomized, open-label, non-inferiority clinical trial compared strategies continuation triple therapy versus monotherapy followed by reinduction nucleosides if virological rebound occurred without genotypic resistance...
Coinfection with hepatitis C virus (HCV) and human immunodeficiency (HIV) is a known risk factor for hepatotoxicity in patients receiving highly active antiretroviral therapy (HAART). The aim of this study was to evaluate the role HCV-related liver fibrosis HAART-associated hepatotoxicity.In prospective involving 107 who underwent biopsy, graded according 5 stages, from F0 (no fibrosis) F4 (cirrhosis). Hepatotoxicity defined as an increase levels aspartate aminotransferase alanine >5 times...
Objective: To assess the rate of long-term effectiveness and factors associated with response to protease inhibitor therapy in a cohort HIV-infected patients. Design setting: Prospective, non-randomized study tertiary care centre. Patients: A total 400 patients who started on (saquinavir, 28%; ritonavir, 26%; indinavir, 46%) from March 1996 1997. Main outcomes measures: Long-term virological immunological were defined as HIV RNA levels below 200 copies/ml CD4+ cell count increase greater...
The OK04 trial has shown that 48 weeks of lopinavir-ritonavir monotherapy with reintroduction nucleosides as needed was noninferior to continuation triple therapy 2 and in patients prior stable suppression. However, it is still uncertain if this experimental strategy can maintain suppression the long term.Patients entered noninferiority (upper limit 95% confidence interval: +12%) no history virological failure while receiving a protease inhibitor plus lopinavir/ritonavir, HIV RNA <50 copies...
Objective The primary objective was to assess the effect of MVC intensification on latently infected CD4+ T cells in chronically HIV-1-infected patients receiving antiretroviral therapy. Methods We performed an open-label pilot phase II clinical trial involving stable therapy whose regimen intensified with 48 weeks maraviroc analyzed latent reservoir, residual viremia and episomal 2LTR DNA examine relationship between these measures HIV-1 immune activation, lymphocyte subsets (including...
HIV patients have seen accelerated ageing. Our objective was to determine the prevalence of frailty, evaluate factors associated with frailty and physical function in older HIV-infected adults. this a cross-sectional study. outpatient clinics two public university hospitals Madrid (Spain). defined according criteria Fried: shrinking, weakness, poor endurance energy, slowness low activity level, being frail those who met at least three criteria, prefrail one or robust when they no criteria....
Abstract Objectives To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive virologically suppressed treatment-experienced individuals in multicentre cohort Spanish HIV/AIDS Research Network (CoRIS) during years 2018–2021. Methods We used multivariable regression models to compare viral suppression (VS) [HIV RNA load (VL) &lt;50 copies/mL] change CD4 cell counts at 24 48 (±12) weeks after initiation with dolutegravir/lamivudine or other...
Background: Hepatitis C virus (HCV) and HIV coinfection constitutes an important epidemiological clinical problem. We evaluated the safety efficacy of Pegylated interferon α2b (Peg-IFN) a fixed dose ribavirin in treatment chronic hepatitis coinfection. Methods: Open, prospective study HCV–HIV coinfected patients with persistently elevated alanine aminotransferase (ALT) levels liver biopsy showing either portal or bridging fibrosis. Therapy included Peg-IFN (50 μg weekly) 800 mg for 48 weeks....
Nucleoside analogues may induce mitochondrial toxicity, particularly didanosine. Ribavirin increases didanosine exposure, which might be clinically relevant when coadministered in HIV/HCV-coinfected patients.To evaluate, among 89 patients receiving highly active antiretroviral therapy (HAART) and for chronic hepatitis C, toxicity those treated with concomitant ribavirin (n=35, 39%).From January 2000 to July 2002 longitudinal analysis of the incidence clinical course didanosine-related...
Objective: To describe the 12-month evolution of lipid profile in HIV-infected virologically suppressed patients substituting tenofovir for stavudine. Design and methods: 'Recover' was a prospective, multicenter, switch study conducted at 120 HIV units across Spain designed to identify single nucleoside analogue substitution due adverse events real practice. Tenofovir substituted stavudine 873 adult patients. No other substitutions were allowed. This sub-study included 352 randomly recruited...
When used in combination, antiretroviral drugs are highly effective for suppressing HIV replication. Nevertheless, treatment failure commonly occurs and is generally associated with viral drug resistance. The choice of an alternative regimen may be guided by a drug-resistance test. However, interpretation resistance from genotypic data poses major challenge.As to current systems, we have developed artificial neural network (ANN) models predict virological response combination therapy...
Objectives: The stability of the reservoir latently infected memory CD4+ T-cells may be associated with continuous replenishment from residual HIV-1, not completely eliminated by otherwise successful antiretroviral therapy (ART). Treatment intensification could help to control virus and modify latent reservoir. objective this work is assess effect intensifying raltegravir on HIV-1 cell Design: A pilot open-label phase-II clinical trial was performed analyze ART after 48 weeks in chronically...
Objective: Rilpivirine (RPV) is the latest approved nonnucleoside reverse transcriptase inhibitor (NNRTI). It displays in-vitro activity extending over other NNRTI-resistant HIV strains. There scarce information about rate of RPV resistance-associated mutations (RAMs) in patients failing NNRTIs. Methods: RAMs were examined plasma samples collected from that had recently failed NNRTI-based regimens at 22 clinics Spain. Results: Resistance tests a total 1064 efavirenz (EFV) (54.5%), nevirapine...
HIV-infected patients had a higher prevalence of insulin resistance (IR) and risk diabetes mellitus (DM) than that observed in healthy controls, but there are no data about the current considering changes HIV presentation use newer antiretroviral drugs.Longitudinal study which involved 265 without DM, receiving first (n=71) advanced lines therapy (n=194).Prevalence IR according to clinical anthropometric variables, including dual X-ray absorptiometry (DXA) scan evaluation. was defined as...
The mechanisms underlying the effect of tenofovir disoproxil fumarate (TDF) on decline bone mineral density (BMD) have not been established, especially renal tubular dysfunction.Longitudinal study 90 patients with two successive dual X-ray absorptiometry scans after evaluation serum and urinary parameters (proteinuria, albuminuria, phosphaturia, uricosuria, glycosuria, β-2-microglobulin, retinol-binding protein).After a median 38 months TDF, osteopenia at spine hip was observed in 49 48%,...
Objectives Sexualized intravenous drug use, also known as slamsex, seems to be increasing among HIV-positive men who have sex with (MSM). Physical and psychopathological symptoms previously been reported in this population, although research on the subject of slamsex is scarce. The objectives our study were describe background a sample MSM engaged during previous year compare physical, psychopathological, drug-related between these participants those non-injecting sexualized use. Design...
Women, particularly those of advanced age with comorbidities and polypharmacy, are often underrepresented in clinical trials evaluating long-acting (LA) antiretroviral therapy (ART) regimens like cabotegravir rilpivirine (CAB + RPV LA). This single-center study aims to address this gap by assessing the effectiveness, tolerability, adherence CAB LA, focusing on women who have complex health profiles. In single-center, retrospective study, we analyzed virologic suppression rates, tolerability...
Background: Recent improvements in the HIV care cascade have reduced incidence high- and middle-income countries, yet late diagnosis remains a critical issue. This study examines impact of two-hour training session on testing rates primary centres Madrid, Spain. Methods: In 2017, we conducted non-mandatory, updated HCV guidelines for providers 20 within Ram&oacute;n y Cajal Hospital area. We compared yearly five years before after intervention. used data from Microbiology...